Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
KimTHHanDHLeeKS.The prevalence of lower urinary tract symptoms in korean men aged 40 years or older: a population-based survey
2) Eylea (aflibercept) Eylea, a recombinant fusion protein approved by the FDA in 2011, is designed to treat patients with neovascular (wet) age-related macular degeneration by inhibiting the binding and activation of cognate VEGF receptors
It accounts for 2%5% of the polypeptides present in BV (Gajski et al., 2024)
Circulation 109(13):15941602
clica06018185 43
US$ 27.15
US$ 20.54
US$ 20.41
US$ 22.91
US$ 26.52
US$ 20.11
US$ 20.43
